Christos Sotiriou

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

S. Loi, V. Nekljudova, C. Schem, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

D. Larsimont, L. Buisseret, M. Ignatiadis, 2023, Nature communications.

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial

L. Buisseret, M. Ignatiadis, L. Craciun, 2023, Journal for ImmunoTherapy of Cancer.

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

J. Bergh, C. Sotiriou, B. Gusterson, 2012, Breast.

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

C. Sotiriou, S. Loi, K. Willard-Gallo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer

Rajarsi R. Gupta, N. Rajpoot, S. Loi, 2024, The Journal of pathology.